Tripegfilgrastim

Phase 2Protein / enzyme

DDong-A ST Co., Ltd.

Tripegfilgrastim is one of 64 small molecule programs targeting Neutropenia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

LymphomaActive, not recruiting

NeutropeniaPhase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Oncaspar

SServier

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Tripegfilgrastim

DDong-A ST Co., Ltd.

Phase 2

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

PEG-Intron

1 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neutropenia1 trial

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

Recruiting·NNational Cancer Center, Korea·Phase 2·NCT06135896·98 enrolled

Lymphoma1 trial

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

Completed·DDong-A ST Co., Ltd.·Phase 1·NCT02963389·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tripegfilgrastim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tripegfilgrastim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tripegfilgrastim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dong-A ST Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: DDong-A ST Co., Ltd.

Tripegfilgrastim

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neutropenia1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News